You are here

FDA Approves Ledipasvir/Sofosbuvir (Harvoni), a Once-Daily, Single-Tablet Regimen for Chronic Hepatitis C

Certain patients with genotype-1 infections need just 8 weeks of treatment

The FDA has approved ledipasvir/sofosbuvir (Harvoni, Gilead Sciences, Inc.), the first once-daily, single-tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults.

The product combines 90 mg of the NS5A inhibitor ledipasvir with 400 mg of the nucleotide analog polymerase inhibitor sofosbuvir (Sovaldi, Gilead). The combination’s efficacy has been established in patients with chronic hepatitis C virus (HCV) genotype-1 infection, with a treatment duration of 8, 12, or 24 weeks, depending on the patient’s prior treatment history, cirrhosis status, and baseline viral load. Eight weeks of treatment with ledipasvir/sofosbuvir can be considered for treatment-naïve patients without cirrhosis who have a baseline HCV viral load below 6 million IU/mL.

The FDA’s approval was supported by data from three phase III studies (ION-1, ION-2, and ION-3). These trials evaluated 8, 12, and 24 weeks of treatment with ledipasvir/sofosbuvir, with or without ribavirin, in nearly 2,000 genotype-1 HCV patients with compensated liver disease. These studies included noncirrhotic treatment-naïve patients (ION-3); cirrhotic and noncirrhotic treatment-naïve patients (ION-1); and cirrhotic and noncirrhotic patients who failed prior therapy with an interferon-based regimen, including regimens containing an HCV protease inhibitor (ION-2). The primary endpoint for each study was the sustained virologic response (HCV undetectable) 12 weeks after completing therapy (SVR12).

Patients who achieve SVR12 are considered to be cured of HCV. In these studies, ribavirin was not shown to increase response rates. Trial participants in the ribavirin-free arms (n = 863) achieved SVR12 rates of 94% to 99%.

Among patients treated for 8, 12, or 24 weeks, adverse events led to treatment discontinuation in 0, less than 1%, and 1%, respectively. Fewer adverse events were observed in the ribavirin-free arms compared with the ribavirin-containing arms in all ION studies. The most common adverse reactions among patients treated with ledipasvir/sofosbuvir (5% or more) were fatigue, headache, nausea, diarrhea, and insomnia.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy